PUBLICATIONS & ABSTRACTS: CLINICAL EVIDENCE
100s of extensive peer reviewed publications and studies utilizing MammaPrint + BluePrint have observed benefits from treatment in the following areas of clinical utility:
Scientific evidence for clinical utility.
By continually expanding and strengthening our database of proven research including 20+ years of clinical validation and 200+ research collaborations, we have gained widespread trust in the precision, accuracy and quality of our MammaPrint® and BluePrint® test suite.
Evidence
Cost Effectiveness of Gene Expression Profiling for Early Stage Breast Cancer: a Decision-Analytic Mode
PUBLICATION: Cancer. 2012 Oct 15;118(20):5163-70. doi: 10.1002/cncr.27443. Epub 2012 Feb 22. AUTHORS: Yang M., Rajan S., Issa A.M. SUMMARY: The model suggested that MammaPrint is a more cost‐effective GEP test compared with Oncotype DX at a threshold willingness‐to‐pay of $50,000 per QALY. Read more: Yang et al_2012_Cancer_Cost Effectiveness of Gene Read More
Head-to-Head Comparison of the 70-gene Signature Versus the 21-Gene Assay: Cost-Effectiveness and the Effect of Compliance
PUBLICATION: Breast Cancer Res Treat. 2012 Jan;131(2):627-36. doi: 10.1007/s10549-011-1769-7. Epub 2011 Sep 24. AUTHORS: Retèl V.P., Joore M.A., van Harten W.H. SUMMARY: The 21-gene has the highest probability of being cost-effective when focusing on cost/LY, while focusing on cost/QALY, the 70-gene signature was most cost-effective. Read more: Breast Cancer Res Read More
Impact of Mammographic Screening on the Detection of Good and Poor Prognosis Breast Cancers
PUBLICATION: Breast Cancer Res Treat. 2011 Dec;130(3):725-34. doi: 10.1007/s10549-011-1748-z. Epub 2011 Sep 4. AUTHORS: Esserman L.J., Shieh Y., Rutgers E.J., Knauer M., Retèl V.P., Mook S., Glas A.M., Moore D.H., Linn S., van Leeuwen F.E., van 't Veer L.J. SUMMARY: In women aged 49-60, the time period of diagnosis significantly Read More
The EORTC 10041/BIG 03-04 MINDACT Trial is Feasible: Results of the Pilot Phase
PUBLICATION: European Journal of Cancer, December 2011, Volume 47, Issue 18, Pages 2742–2749. AUTHORS: Emiel Rutgers, Martine J. Piccart-Gebhart, Jan Bogaerts, Suzette Delaloge, Laura Van ‘t Veer, Isabel Teresa Rubio, Giuseppe Viale, Alastair M. Thompson, Rodolfo Passalacqua, Ulrike Nitz, Anita Vindevoghel, Jean-Yves Pierga, Peter M. Ravdin, Gustavo Werutsky, Fatima Cardoso Read More
Use of a Genomic Test (MammaPrint™) in Daily Clinical Practice to Assist in Risk Stratification of Young Breast Cancer Patients
PUBLICATION: Arch Gynecol Obstet (2011) 283: 597. https://doi.org/10.1007/s00404-010-1454-9. AUTHORS: Kunz, G. SUMMARY: 44 patients had MammaPrint results and were eligible for the analysis. The results revealed a low risk result in 29 patients and a high risk result in 15 patients. Read more: Kunz_2011_Arch Gynecol Obstet._Use of a Genomic Test Read More
Gene Expression Profiles from Formalin Fixed Paraffin Embedded Breast Cancer Tissue are Largely Comparable to Fresh Frozen Matched Tissue
PUBLICATION: PLoS One. 2011 Feb 11;6(2):e17163. doi: 10.1371/journal.pone.0017163. AUTHORS: Mittempergher L., de Ronde J.J., Nieuwland M., Kerkhoven R.M., Simon I., Rutgers E.J., Wessels L.F., Van't Veer L.J. SUMMARY: We demonstrate that data generated from FFPE material with the DASL assay, if properly processed, are comparable to data extracted from the Read More
Cost-effectiveness of 70-gene MammaPrint Signature in Node-Negative Breast Cancer
PUBLICATION: Am J Manag Care. 2010 Dec 1;16(12):e333-42. AUTHORS: Chen E., Tong K.B., Malin J.L. SUMMARY: 70-gene signature reclassified 29% of patients and spared 10% of patients from chemotherapy. Results of this modeling analysis suggest that treatment guided by 70-gene signature may be associated with a decrease in chemotherapy use Read More